Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects.

María Angeles Pena Pardo Javier Muriel Miriam Saiz-Rodriguez Alberto M Borobia Francisco Abad-Santos Jesús Frías Ana María Peiró

Published in: Clinical drug investigation (2020)

CYP2B6 G516T and CYP3A4 *20,*22 polymorphisms could influence imatinib plasma concentrations and safety profile, after single-dose administration to healthy subjects. This finding needs to be confirmed before it is implemented in clinical practice in oncological patients under treatment with imatinib.

Keyphrases

chronic myeloid leukemia
clinical practice
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
prostate cancer
patient reported outcomes
combination therapy
smoking cessation